Prostaglandin E2
Based on 60 publication(s) in Google Scholar
Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.64%
- CAS. Nr.: 363-24-6
- Formel: C20H32O5
- Molecular Weight:352.47
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Lipid Compound Library
HY-L043
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Angiogenesis-Related Compound Library
HY-L088
-
Food-Sourced Compound Library
HY-L094
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Animal-Sourced Natural Product Library
HY-L157
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Fatty Acids Compound Library
HY-L182
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Human Hormone Compound Library
HY-L211
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lipid Metabolite Compound Library
HY-L228
-
Chinese Baijiu Compound Library
HY-L241
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Prostaglandin E2
More- Signal Transduct Target Ther. 2026 Jun 4;11(1):215.
- Nature. 2025 Jul;643(8070):192-200. [Abstract]
- Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
- Cell. 2024 Jun 6;187(12):2935-2951.e19. [Abstract]
- Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]
- Nat Biomed Eng. 2023 Mar;7(3):281-297. [Abstract]
- Ann Rheum Dis. 2025 Oct 28:S0003-4967(25)04428-0. [Abstract]
- Cell Stem Cell. 2021 Sep 2;28(9):1597-1613.e7. [Abstract]
- Adv Funct Mater. 2025 Apr 21.
- Cancer Res. 2026 Jan 22. [Abstract]
- Nat Commun. 2026 Jun 8. [Abstract]
- Nat Commun. 2025 Aug 30;16(1):8124. [Abstract]
- Nat Commun. 2024 Sep 12;15(1):7996. [Abstract]
- Adv Sci (Weinh). 2026 Mar 13:e20695. [Abstract]
- Exp Hematol Oncol. 2025 Mar 22;14(1):43. [Abstract]
- J Exp Clin Cancer Res. 2020 Jun 16;39(1):113. [Abstract]
- Int J Oral Sci. 2025 Apr 16;17(1):29. [Abstract]
- Int J Oral Sci. 2023 Sep 7;15(1):38. [Abstract]
- J Biomed Sci. 2023 Aug 2;30(1):62. [Abstract]
- Asian J Pharm Sci. 2026 Jun 20.
- Engineering. 2025 Jul 30.
- Cell Rep Med. 2026 Feb 17;7(2):102622. [Abstract]
- Cell Rep Med. 2025 Feb 18;6(2):101966. [Abstract]
- J Neuroinflammation. 2025 Oct 14;22(1):233. [Abstract]
- Genes Dis. 2026 Jun 15.
- Nano Res. 2023 Aug 8.
- Acta Pharmacol Sin. 2025 May;46(5):1404-1418. [Abstract]
- EMBO J. 2024 Nov;43(21):5018-5036. [Abstract]
- Free Radic Biol Med. 2023 Oct 5;209(Pt 1):1-8. [Abstract]
- J Orthop Translat. 2024 Nov 5:49:325-338. [Abstract]
- Aging Cell. 2026 Feb;25(2):e70374. [Abstract]
- Cell Rep. 2023 May 23;42(6):112546. [Abstract]
- Clin Transl Med. 2023 Jul;13(7):e1333. [Abstract]
- J Agric Food Chem. 2026 May 20;74(19):15073-15087. [Abstract]
- Cell Biosci. 2025 Mar 27;15(1):39. [Abstract]
- J Bone Miner Res. 2023 Jan;38(1):214-227. [Abstract]
- Biochem Pharmacol. 2023 Feb:208:115403. [Abstract]
- Cells. 2022 Jun 9;11(12):1870. [Abstract]
- Front Pharmacol. 2021 Jul 14:12:684538. [Abstract]
- Front Cell Infect Microbiol. 2021 Jul 9:11:669623. [Abstract]
- Front Microbiol. 2020 May 20;11:987. [Abstract]
- J Cell Mol Med. 2026 Jan;30(1):e70992. [Abstract]
- J Cell Mol Med. 2021 Nov;25(22):10389-10402. [Abstract]
- iScience. 2025 Sep 9;28(10):113520. [Abstract]
- J Cell Commun Signal. 2020 Jun;14(2):175-192. [Abstract]
- Cell Signal. 2023 Aug:108:110707. [Abstract]
- Eur J Med Res. 2024 Dec 20;29(1):611. [Abstract]
- Autoimmunity. 2023 Dec;56(1):2193678. [Abstract]
- Biol Reprod. 2022 Jan 13;106(1):155-172. [Abstract]
- Neurogastroenterol Motil. 2025 Jun 22:e70104. [Abstract]
- Oncotargets Ther. 2020 Aug 18;13:8197-8208. [Abstract]
- J Pediatr Surg. 2019 Oct;54(10):2032-2037. [Abstract]
- In Vitro Model. 2025 Mar 5;4(1):31-44. [Abstract]
- PeerJ. 2024 Jul 10:12:e17722. [Abstract]
- Head Neck. 2025 Feb;47(2):504-516. [Abstract]
- Res Sq. 2026 Jan 7.
- SSRN. 2025 Feb 6.
- Res Sq. 2025 Feb 03.
- Research Square Preprint. 2024 Mar 28.
- Authorea. 2023 Aug 14.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
WB
-
WB
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
EP |
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
1.9 nM
Compound: Prostaglandin E2
|
Agonist activity at human EP2 receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method
Agonist activity at human EP2 receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method
|
[PMID: 26985320] |
| CHO | EC50 |
2.5 nM
Compound: Prostaglandin E2
|
Agonist activity at human EP3 receptor expressed in CHO cells assessed as increase in intracellular calcium level by fluorescence based analysis
Agonist activity at human EP3 receptor expressed in CHO cells assessed as increase in intracellular calcium level by fluorescence based analysis
|
[PMID: 26985320] |
| CHO | EC50 |
3.7 nM
Compound: Prostaglandin E2
|
Agonist activity at human EP1 receptor expressed in CHO cells assessed as increase in intracellular calcium level by fluorescence based analysis
Agonist activity at human EP1 receptor expressed in CHO cells assessed as increase in intracellular calcium level by fluorescence based analysis
|
[PMID: 26985320] |
| CHO | EC50 |
347 nM
Compound: Prostaglandin E2
|
Agonist activity at human IP receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method
Agonist activity at human IP receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method
|
[PMID: 26985320] |
| CHO | EC50 |
7.5 nM
Compound: Prostaglandin E2
|
Agonist activity at human EP4 receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method
Agonist activity at human EP4 receptor expressed in CHO cells assessed as increase in intracellular cAMP level after 30 mins by HTRF method
|
[PMID: 26985320] |
| HEK293 | EC50 |
3 nM
Compound: PGE2
|
EP4 agonist potency utilizing a stable clone of pSV40-EP4 transfected into HEK293 cells expressing EP4 receptor
EP4 agonist potency utilizing a stable clone of pSV40-EP4 transfected into HEK293 cells expressing EP4 receptor
|
[PMID: 12643927] |
| HEK293 | IC50 |
0.7 nM
Compound: PGE2
|
Inhibitory activity against human EP4 receptor expressed in HEK293 ebna cells
Inhibitory activity against human EP4 receptor expressed in HEK293 ebna cells
|
[PMID: 12643927] |
| HEK293 | EC50 |
0.2 nM
Compound: 1
|
Agonist activity against rat EP2 receptor expressed in HEK293 cells assessed as stimulation of cAMP release
Agonist activity against rat EP2 receptor expressed in HEK293 cells assessed as stimulation of cAMP release
|
[PMID: 19250823] |
| HEK293 | EC50 |
0.7 nM
Compound: 1
|
Agonist activity against rat EP4 receptor expressed in HEK293 cells assessed as stimulation of cAMP release
Agonist activity against rat EP4 receptor expressed in HEK293 cells assessed as stimulation of cAMP release
|
[PMID: 19250823] |
| HEK293 | IC50 |
2.1 nM
Compound: 1
|
Inhibition of rat EP4 receptor expressed in HEK293 cells
Inhibition of rat EP4 receptor expressed in HEK293 cells
|
[PMID: 19250823] |
| HEK293 | IC50 |
5.2 nM
Compound: 1
|
Inhibition of rat EP2 receptor expressed in HEK293 cells
Inhibition of rat EP2 receptor expressed in HEK293 cells
|
[PMID: 19250823] |
| HEK293 | EC50 |
346 nM
Compound: Prostaglandin E2
|
Agonist activity at PK2-tagged human EP2 receptor expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin recruitment incubated for 90 mins by beta-galactosidase reporter gene assay
Agonist activity at PK2-tagged human EP2 receptor expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin recruitment incubated for 90 mins by beta-galactosidase reporter gene assay
|
[PMID: 26985320] |
| HEK293 | IC50 |
2.6 nM
Compound: PGE2
|
Displacement of [3H]PGE2 from human recombinant prostanoid EP2 receptor expressed in HEK293 cells
Displacement of [3H]PGE2 from human recombinant prostanoid EP2 receptor expressed in HEK293 cells
|
[PMID: 26988801] |
| HEK293 | IC50 |
2.6 nM
Compound: PGE2
|
Displacement of [3H]PGE2 from human recombinant EP2 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method
Displacement of [3H]PGE2 from human recombinant EP2 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method
|
[PMID: 27876250] |
| HEK293 | IC50 |
2.6 x 10-9 M
Compound: PGE2
|
Displacement of [3H]PGE2 from human recombinant EP2 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method
Displacement of [3H]PGE2 from human recombinant EP2 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method
|
[PMID: 27876250] |
| HEK293 | IC50 |
5.5 x 10-10 M
Compound: PGE2
|
Displacement of [3H]PGE2 from human recombinant EP4 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method
Displacement of [3H]PGE2 from human recombinant EP4 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method
|
[PMID: 27876250] |
| HEK293 | IC50 |
4 nM
Compound: PGE2
|
Displacement of [3H]prostaglandin E2 from human EP2 receptor expressed in HEK293 cell membranes after 60 mins by liquid scintillation counting
Displacement of [3H]prostaglandin E2 from human EP2 receptor expressed in HEK293 cell membranes after 60 mins by liquid scintillation counting
|
[PMID: 29995405] |
| K562 | IC50 |
63 μM
Compound: 3
|
In vitro antiproliferative activity was measured on human leukemia K562 cells
In vitro antiproliferative activity was measured on human leukemia K562 cells
|
10.1016/S0960-894X(00)80372-8 |
PGE2 shows inhibition of IL 2 production in the mixture of irradiated and nonirradiated T lymphocytes. PGE2 (0.1-10 μM) dose-dependently inhibits the production of IL 2. PGE2 acts during the inductive phase of activation of suppressor cells. Preincubation of T lymphocytes with PGE2 induces cells that suppress IL 2 production and PHA proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Prostaglandin E2 can be used in animal modeling to construct a rat pain model.
PGE2 (0.3 μg/k, i.p.) significantly reduces the number of peritoneab macrophages undergoing phagocytosis of the methacrybate microbeads in rats[2]. PGE2 (0.1 mg/min, i.a.) increases renal blood flow. PGE2 produces a biphasic change in renal vascular resistance, vasodilatation starts at 0.01 mg/min and is maximal at about 3 mg/min, while at the highest dose used (20 mg/min) PGE2 induces renal vasoconstriction[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 363-24-6
-
Appearance Solid
-
Molecular Weight 352.47
-
Formel C20H32O5
-
Color White to off-white
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)C/C=C\CCCC(O)=O
-
Synonyms
PGE2; Dinoprostone
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 2 years -20°C 1 year
Publications (60)
-
Journal Impact Factor
-
Most Recent
-
-
Nature
2025 Jul;643(8070):192-200. PMID: 39695227 -
Cell
2025 Dec 11;188(25):7291-7308.e23. PMID: 41161316 -
Cell
Innervation of nociceptor neurons in the spleen promotes germinal center responses and humoral immunity. [Abstract]2024 Jun 6;187(12):2935-2951.e19. PMID: 38772371 -
Cell
2023 Dec 7;186(25):5500-5516.e21. PMID: 38016470 -
Nat Biomed Eng
Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. [Abstract]2023 Mar;7(3):281-297. PMID: 36941352 -
Ann Rheum Dis
2025 Oct 28:S0003-4967(25)04428-0. PMID: 41162285 -
Cell Stem Cell
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. [Abstract]2021 Sep 2;28(9):1597-1613.e7. PMID: 33945793 -
-
Cancer Res
ACSL5 Mediates Adaptation to the Palmitic Acid-Enriched Pulmonary Microenvironment to Enhance Metastatic Breast Cancer Cell Survival and Lung Metastasis. [Abstract]2026 Jan 22. PMID: 41570334 -
Nat Commun
2026 Jun 8. PMID: 42259794 -
Nat Commun
2025 Aug 30;16(1):8124. PMID: 40885756 -
Nat Commun
Engineered model of heart tissue repair for exploring fibrotic processes and therapeutic interventions. [Abstract]2024 Sep 12;15(1):7996. PMID: 39266508 -
Adv Sci (Weinh)
Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling. [Abstract]2026 Mar 13:e20695. PMID: 41824764 -
Exp Hematol Oncol
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway. [Abstract]2025 Mar 22;14(1):43. PMID: 40121502
Prostaglandin E2 purchased from MedChemExpress. Usage Cited in: Exp Hematol Oncol. 2025 Mar 22;14(1):43. [Abstract]
Prostaglandin E2 (PGE2) (1 μM) can reverse the inhibition of Kasumi-1 and Molm-13 cells proliferation caused by MMP14 knockdown.
-
J Exp Clin Cancer Res
3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE2 pathway. [Abstract]2020 Jun 16;39(1):113. PMID: 32546278
Prostaglandin E2 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Jun 16;39(1):113. [Abstract]
WB results showed that DIM could partly reverse the EMT process which could be enhanced by PGE2 (Prostaglandin E4) (10 μM) treatment.
-
Int J Oral Sci
2025 Apr 16;17(1):29. PMID: 40240323 -
Int J Oral Sci
Single-cell transcriptomic analysis uncovers the origin and intratumoral heterogeneity of parotid pleomorphic adenoma. [Abstract]2023 Sep 7;15(1):38. PMID: 37679344 -
J Biomed Sci
Exosomal PGE2 from M2 macrophages inhibits neutrophil recruitment and NET formation through lipid mediator class switching in sepsis. [Abstract]2023 Aug 2;30(1):62. PMID: 37533081
Prostaglandin E2 purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2023 Aug 2;30(1):62. [Abstract]
Prostaglandin E2 (PGE2) (100 nM) increases15-LO expression in both SP and SP + M0-Exo-treated PMNs .
-
-
-
Cell Rep Med
A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma. [Abstract]2026 Feb 17;7(2):102622. PMID: 41707653 -
Cell Rep Med
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. [Abstract]2025 Feb 18;6(2):101966. PMID: 39970873 -
J Neuroinflammation
IL-1β+ tumor-associated macrophages accelerate glioblastoma progression by amplifying the PGE2-EP4 signaling. [Abstract]2025 Oct 14;22(1):233. PMID: 41088217 -
-
-
Acta Pharmacol Sin
Organoid modeling identifies USP3-AS1 as a novel promoter in colorectal cancer liver metastasis through increasing glucose-driven histone lactylation. [Abstract]2025 May;46(5):1404-1418. PMID: 39837984 -
EMBO J
TNFSF14+ natural killer cells prevent spontaneous abortion by restricting leucine-mediated decidual stromal cell senescence. [Abstract]2024 Nov;43(21):5018-5036. PMID: 39261664
Prostaglandin E2 purchased from MedChemExpress. Usage Cited in: EMBO J. 2024 Nov;43(21):5018-5036. [Abstract]
Decidualized hESCs were induced with PGE2 (1 μM) plus MPA (1μM) for 48h, and then expression of CDKN2A, CDKN1A and TP53 was measured by western blot (n=3 biological 4 replicates per group), relative expression levels of proteins were standardized using internal. reference GAPDH.
-
Free Radic Biol Med
H2O2 enhances the spontaneous phasic contractions of isolated human-bladder strips via activation of TRPA1 channels on sensory nerves and the release of substance P and PGE2. [Abstract]2023 Oct 5;209(Pt 1):1-8. PMID: 37802373 -
J Orthop Translat
Sensory nerve EP4 facilitates heterotopic ossification by regulating angiogenesis-coupled bone formation. [Abstract]2024 Nov 5:49:325-338. PMID: 39568804 -
Aging Cell
Decreased PTGES2 Farnesylation in Granulosa Cells Compromises PGE2-Dependent Cumulus Expansion and Oocyte Maturation During Ovarian Aging. [Abstract]2026 Feb;25(2):e70374. PMID: 41521701 -
Cell Rep
2023 May 23;42(6):112546. PMID: 37224015 -
Clin Transl Med
Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway. [Abstract]2023 Jul;13(7):e1333. PMID: 37478294 -
J Agric Food Chem
Ovotransferrin Alleviates Ulcerative Colitis by Modulating Ligilactobacillus murinus-Mediated Bile Acid Metabolism via the Ptgs2/JAK-STAT Signaling Axis. [Abstract]2026 May 20;74(19):15073-15087. PMID: 42098593 -
Cell Biosci
2025 Mar 27;15(1):39. PMID: 40148998 -
J Bone Miner Res
Osteoblastic STAT3 is Crucial for Orthodontic Force Driving Alveolar Bone Remodeling and Tooth Movement. [Abstract]2023 Jan;38(1):214-227. PMID: 36370067 -
Biochem Pharmacol
ALA-PDT Augments Intense Inflammation in the Treatment of Acne Vulgaris by COX2/TREM1 Mediated M1 Macrophage Polarization. [Abstract]2023 Feb:208:115403. PMID: 36592708 -
Cells
Prostaglandin 2α Promotes Autophagy and Mitochondrial Energy Production in Fish Hepatocytes. [Abstract]2022 Jun 9;11(12):1870. PMID: 35740999 -
Front Pharmacol
Role of Serosal TRPV4-Constituted SOCE Mechanism in Secretagogues-Stimulated Intestinal Epithelial Anion Secretion. [Abstract]2021 Jul 14:12:684538. PMID: 34335254 -
Front Cell Infect Microbiol
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. [Abstract]2021 Jul 9:11:669623. PMID: 34307194 -
Front Microbiol
Cyclooxygenase-2 Facilitates Newcastle Disease Virus Proliferation and Is as a Target for Canthin-6-One Antiviral Activity. [Abstract]2020 May 20;11:987. PMID: 32508794 -
J Cell Mol Med
Quercetin Alleviates Osteoarthritis Pain by Inhibiting Vascular Endothelial Growth Factor A Through Regulating cGAS/STING Pathway. [Abstract]2026 Jan;30(1):e70992. PMID: 41474220 -
J Cell Mol Med
Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress. [Abstract]2021 Nov;25(22):10389-10402. PMID: 34609050 -
iScience
ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. [Abstract]2025 Sep 9;28(10):113520. PMID: 41069850 -
J Cell Commun Signal
Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2/PGE2/STAT3 axis. [Abstract]2020 Jun;14(2):175-192. PMID: 31925646 -
Cell Signal
The 15-hydroxyprostaglandin dehydrogenase inhibitor SW033291 ameliorates abnormal hepatic glucose metabolism through PGE2-EP4 receptor-AKT signaling in a type 2 diabetes mellitus mouse model. [Abstract]2023 Aug:108:110707. PMID: 37164143 -
Eur J Med Res
Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2. [Abstract]2024 Dec 20;29(1):611. PMID: 39702296 -
Autoimmunity
LncRNA DGCR5/miR-204-5p/SRSF7 axis regulates PDGF-BB-induced proliferation and migration of airway smooth muscle cells with potential role in asthma. [Abstract]2023 Dec;56(1):2193678. PMID: 37066515 -
Biol Reprod
Single-cell analysis of prostaglandin E2-induced human decidual cell in vitro differentiation: a minimal ancestral deciduogenic signal†. [Abstract]2022 Jan 13;106(1):155-172. PMID: 34591094 -
Neurogastroenterol Motil
Shugan Decoction Ameliorated WAS-Induced Abnormal Colonic Motility in Rats by Inhibiting Colonic TRPV4-PGE2 Signaling. [Abstract]2025 Jun 22:e70104. PMID: 40545667 -
Oncotargets Ther
Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma. [Abstract]2020 Aug 18;13:8197-8208. PMID: 32904445 -
J Pediatr Surg
MPGES-1 derived PGE2 inhibits cell migration by regulating ARP2/3 in the pathogenesis of Hirschsprung disease. [Abstract]2019 Oct;54(10):2032-2037. PMID: 30814036 -
In Vitro Model
Colorectal carcinoma organoid and cancer-associated fibroblasts co-culture system for drug evaluation. [Abstract]2025 Mar 5;4(1):31-44. PMID: 40160212 -
PeerJ
Ginkgetin attenuates bone loss in OVX mice by inhibiting the NF-κB/IκBα signaling pathway. [Abstract]2024 Jul 10:12:e17722. PMID: 39006031 -
Head Neck
2025 Feb;47(2):504-516. PMID: 39290130 -
-
-
-
-
Lösungsmittel & Löslichkeit
DMSO : 200 mg/mL (567.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (14.19 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (14.19 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
Lymphocytes in CM (1×106 cells/mL) are ditributed in microculture plates (100 μL) in triplicate in the presence of PGE-treated T cells or medium-treated T cells and stimulated with PHA-P at various mitogenic doses. After 72 hr, cultures are pulsed with 1 μCi [3H]thymidine per well (specific activity 5 Ci/mM) for 16 to 18 hr, collected with amicroprecipltator, dried, and counted in a liquid scintillation counter.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Male Sprague Dawley rats (200-250 g) are used throughout the study. For 3 consecutive days rats in the experimental groups receive a daily intraperitoneal injection of either PGE2 (0.3 μg/kg body weight (BW)), the prostaglandin inhibitor mecbofenamate (10 mg/kg BW) or the prostaglandin precursor arachidonic acid (0.3 μg/ kg BW). To determine whether or not 0.3 μg/kg BW of a fatty acid produces nonspecific effects, the biologically inactive fatty acid 11, 14, 17-eicosatrienoic acid is also administered to a group of rats. Rats in the control group receive an equivalent volume (2.0 mL/kg BW) of the vehicle. On the third day, 3 mL of a suspension containing 1.2×106 fluorescent methacrylate microbeads/mL of PBS are injected intraperitoneally (ip) into each rat. Six hours later all animals are given ip a regular dose of their respective treatment. Peritoneal exudate cells are harvested 19-22 hr later.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Chouaib S, et al. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol. 1984 Apr;132(4):1851-7. [Content Brief]
[2]. Fernandez-Repollet E, et al. In vivo effects of prostaglandin E2 and arachidonic acid on phagocytosis of fluorescent methacrylate microbeads by rat peritoneal macrophages. J Histochem Cytochem. 1982 May;30(5):466-70. [Content Brief]
[3]. Haylor J, et al. Renal vasodilator activity of prostaglandin E2 in the rat anaesthetized with pentobarbitone. Br J Pharmacol. 1982 May;76(1):131-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8371 mL | 14.1856 mL | 28.3712 mL | 70.9280 mL |
| 5 mM | 0.5674 mL | 2.8371 mL | 5.6742 mL | 14.1856 mL | |
| 10 mM | 0.2837 mL | 1.4186 mL | 2.8371 mL | 7.0928 mL | |
| 15 mM | 0.1891 mL | 0.9457 mL | 1.8914 mL | 4.7285 mL | |
| 20 mM | 0.1419 mL | 0.7093 mL | 1.4186 mL | 3.5464 mL | |
| 25 mM | 0.1135 mL | 0.5674 mL | 1.1348 mL | 2.8371 mL | |
| 30 mM | 0.0946 mL | 0.4729 mL | 0.9457 mL | 2.3643 mL | |
| 40 mM | 0.0709 mL | 0.3546 mL | 0.7093 mL | 1.7732 mL | |
| 50 mM | 0.0567 mL | 0.2837 mL | 0.5674 mL | 1.4186 mL | |
| 60 mM | 0.0473 mL | 0.2364 mL | 0.4729 mL | 1.1821 mL | |
| 80 mM | 0.0355 mL | 0.1773 mL | 0.3546 mL | 0.8866 mL | |
| 100 mM | 0.0284 mL | 0.1419 mL | 0.2837 mL | 0.7093 mL |
Prostaglandin E2 Related Classifications
HY-101952 Related Classifications
Powered by Bioz